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Abstract The aim of this study was to verify the clinical
efficacy of a diet associated with already commercially
available oral amino acid functional cluster (AFC) compared
to the administration of a diet associated with a nitrogen
protein-based supplement (casein) in antagonizing malnutri-
tion in patients with Chronic renal failure (CRF) undergoing
haemodialysis. The secondary aim was to assess the changes
in protein levels during the acute phase such as the expression
of inflammatory cytokines. Twenty patients in haemodialysis
aged between 18 and 85 of both genders (13 m, 7f) were
recruited, randomized and divided into two groups and treated
for 4 months respectively with: (1) oral AFC supplement
(*)8 g/die: group A, and (2) oral supplementation of a protein
nitrogenous mixture compared to AFC with a casein protein
source) of 6.6 g: group P. During the initial assessment and
thereafter on a monthly basis all patients underwent the fol-
lowing: Dietary recall 24 h; Anthropometric: Weight, height,
BMI, expected dry weight, actual weight; Biochemical:
Albumin, transferrin, Na, K, Cl, Ca, P, Mg, long-interval
creatinine (Aminotrofic: Errekappa Euroterapici, Milano)
pre-albumin, a1 acid glycoprotein, C reactive protein (CRP),
protein nitrogen appearance (PNA); Instrumental: Handgrip
strength evaluation, Calorimetry by means of Armband, Bio-
impedance analysis (BIA), Spitzer Index (quality of life),
Subjective Global Assessment Generated by the patient (PG
SGA). Considering the nutritional parameters, no significant
differences concerning dry weight emerged between the
beginning (T0) and the end (T4) (weight A to T0: kg
64.41 ± 6.34; weight A to T4: kg 64.51 ± 7.05: P = NS;
weight P to T0: kg 60.17 ± 11.94; weight P to T4: kg 59.86 ±
11.43: P = NS); biochemical parameters, significant differ-
ences were observed only for two parameters: pre-albumin
(Pre-albumin A to T0 30.12 ± 7.23; Pre-albumin A to T4:
28.91 ± 5.8; Pre-albumin P to T0 22.51 ± 6.04; Pre-albumin
P to T4: 26.10 ± 9.82), and Transferrin (Transferrin A to T0
171.77 ± 28.87 mg/dL, Transferrin A to T4: 181.44 ±
38.83 mg/dL: P \ 0.005; Transferrin P to T0 160.29 ±
27.46 mg/dL, Transferrin P to T4: 146.57 ± 24.96 mg/dL:
P \ 0.005), but not in other parameters. From a nutritional
perspective, after 4 months of treatment an increase in protein
synthesis was noted in group A compared to group P which
was proved by the significant increase of transferrin. This pilot
study suggests the AFC oral supplementation may represent a
valid alternative to intradialytic parenteral treatment and may
also allow for an improvement in blood chemical values and
nutritional status.
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Introduction
Chronic renal failure (CRF) is defined as the progressive
and irreversible loss of the secretory and metabolic
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capacity of the kidney, affecting, In Italy approximately
150 cases per million inhabitants. The incidence of CRF is
continually increasing with more than 8,000 new dialysis
treatments being registered every year [1, 2].
The prevalence of malnutrition during CRF is high
(18–56 % of cases), both while undergoing conservative
treatment and during haemodialysis. Furthermore, CRF is
almost constant during the advanced stages of uremia [3].
The establishment of malnutrition is associated with
several factors: inter-current complications like acidosis
and infections [4]; anorexia, reduced food intake; hormonal
changes (hyperparathyroidism, insulin-resistance, etc.);
uremic toxemia and its consequences on the gastrointesti-
nal tract [5–7]; loss of nutrients and the induction of protein
catabolism through dialytic treatment (an average loss of
10–12 g of amino acids for every session of haemodialysis
and 12–15 g for every peritoneal dialysis), [7]. Moreover,
the malnutrition setting during CRF is frequently associ-
ated (25 %) with chronic systemic inflammation which is
seen in patients in the pre-dialytic phase and is character-
ized by an increase in reactive C-protein (RCP), interleukin
(IL)-6, fibrinogen, ferritin and beta2-macro globulin which
represents an unfavourable prognostic factor [5–7].
The aims of nutritional treatment are: (1) to prevent
malnutrition in the initial stages of CRF and/or maintain an
optimal nutritional state aimed at reducing or controlling
the accumulation of products of degradation; (2) to prevent
diseases of the cardiovascular system and the osteo-articular
apparatus by treating hyperlipidemia, vitamin deficiency and
hyperparathyrodism; (3) to delay the progression of renal
failure [8, 9].
In CRF patients, the caloric requirements appear to be
affected more by the presence of acute and/or concurrent
complications during the clinical course than by the
reduction of renal function, which in itself does not reduce
the energetic balance. In general, a non-protein intake
equal to 25–30 kcal/kg/die (1–1.5 g/kg/die) is suggested
and should be administered over 24 h [10–13].
Protein requirements vary on the basis of the patient’s
clinical condition and furthermore an assessment of whe-
ther the patient is to undergo conservative or substitute
treatment is necessary [14].
While a protein intake B0.8 g/kg/die is suggested for
CRF patients not undergoing haemodialysis this amount is
inadequate for the majority of haemodialysis patients. The
introduction of 1.1 g of protein/kg/die (with at least 50 %
of high biological value protein) can supply a sufficient
contribution of protein in some haemodialysis patients, but,
in the vast majority of clinically stable patients who
introduce 25 or 35 kcal/kg/die, this is insufficient in
maintaining a balanced nutritional state [15]. Therefore, the
introduction of at least 1.2 g protein/kg is recommended in
order to maintain a stable or a positive nitrogen balance
and it is mandatory that the protein quota is represented by
at least 50 % high biological level protein. However, from
a practical point of view, it is difficult for patients to
maintain such a rigorous daily protein intake; thus, it is
pivotal that patients are encouraged to respect dietary
indications and the specific recommended dietary regimen.
On the opposite side when the intake of a sufficient protein
amount cannot be reached, the addition of dietary protein
supplements is necessary. In such cases, considering that
proteins are the major source of phosphorous and hydrogen
ions, a change in treatment will be necessary (intensity and
duration of dialytic treatment, phosphate binders, alkalizers).
An alternative to the use of proteins could be repre-
sented by amino acids.
Recently a mixture of oral amino acid functional cluster
(AFC) has been proposed. This formula appears to have
been developed in order to adapt to the stoichiometric ratio
of essential amino acids stimulating protein muscle syn-
thesis and replenishing the level of mitochondrial ATP to
the level of the cardiac muscle in conditions such as dia-
betes and chronic heart failure [16, 17].
In particular the mixture of amino acids was studied by
Pasini et al. [18], who assessed the anti-ischaemic effects in
the short- and long-term in an experimental model of iso-
lated hearts in rats. Long-term treatment of AFC reduces
the increase of arterial pressure, maintains the ATP content
during ischaemia and improves blood pressure at the end of
post-ischaemic reperfusion. In man, in a crossover, ran-
domized trial by Solerte et al. [19], AFC improved meta-
bolic compensation through the reduction of insulin levels,
insulin-resistance, post-prandial glycaemia and glycated
haemoglobin.
A further double-blind placebo-controlled randomized
study by Aquilani et al. [20], showed that conventional
treatment with AFC increased physical capacity improving
circulation, the use of oxygen by the muscle and the pro-
duction of aerobic energy in elderly patients studied.
Furthermore, the efficacy of the formula in malnour-
ished humans with CRF is still under investigation.
The aim of the study is to verify the clinical efficacy of a
diet supplemented by AFC compared to the administration
of a diet supplemented by protein (casein in a isonitroge-
nous mood) in antagonizing malnutrition in patients with
CRF undergoing haemodialytic treatment.
Materials and methods
The study was a prospective, randomized, double blind,
controlled clinical trial and it was approved by the Medical
Ethics Committee of the ASL4 Chiavarese.
In the period 2008–2010 all the patients undergoing
hemodialysis, who were malnourished according to the
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classification of the Patient Generated Subjective Global
Assessment (PG SGA B ? C) were screened [21].
Exclusion criteria were: extremely critical clinical con-
ditions; well -nourished; aged over [85 years; previous
supplement treatment quitted less than 1 month; acute
myocardial infarction before less than 1 month; previous
TIA or smoke or cancer.
Twenty patients in haemodialysis aged between 18 and 85
of both genders (13 m, 7f) were included, randomized, divided
into two groups and treated for 4 months respectively with:
1. Oral AFC supplement (Table 1) 8 g/day: (group A).
2. Oral casein supplementation of isonitrogenous to AFC,
6.6 g/day: (group P).
The products were produced and blinded in Italy
(Errekappa Euroterapici Milano, Italy).
All patients received a personalized diet addressing the
patients nutritional requirements (25 kcal/kg/day non-pro-
teic; protein: 1.2 g/kg/day).
Associated treatments
When patients were undergoing haemodialysis no changes
to treatment were made.
During the initial assessment and thereafter on a monthly
basis all patients underwent the following evaluations:
24 h Dietary recall
Anthropometric measurements
Weight, height, BMI, expected dry weight, actual weight;
Biochemical
Albumin, transferrin, Na, K, Cl, Ca, P, Mg, long-interval
creatinine,2 pre-albumin, a1 acid glycoprotein, C reactive
protein (CRP), protein nitrogen appearance (PNA).
Instrumental
Handgrip strength evaluation, calorimetry by means of
Armband, Bio-impedance analysis (BIA), Spitzer Index
(quality of life) [22], Patient Generated Subjective Global
Assessment (PG SGA) [21].
BMI
Body Mass Index (BMI) was calculated as follows: [(weight
in kg)/(height in m2)].
BIA
BIA (Bioelectric Impedance Analysis-Akern Spa) mea-
surement was carried out through a bio-impedance ana-
lyzer (using electrodes at 800 mA and 50 kHz).
Data for body composition were taken from the corre-
lation between resistance and reactance.
Patients lie on their back with arms and legs turned
outwards so that the central surfaces of the extremities do
not touch while BMI measurements were taken. Electrodes
were positioned between the hand and foot of the dominant
side.
Handgrip strength evaluation: measurement of the
handgrip was taken with a dynamometer; Jamar, Chicago,
IL).
Patients were asked to sit comfortably with their
shoulders brought forward and elbows flexed at a 90 angle
and then to squeeze with maximum force first with one
hand, then the other. Each test was repeated three times and
the highest value in kg was chosen.
Calorimetry detailed assessment of daily physical
activity and the associated energy expenditure was carried
out using a specially designed electronic instrument
(SenseWear, Armband, SensorMedics Italia Srl), which
measures total energy expenditure TEE (REE-resting
energy expenditure—added to energy used for physical
activity).
PC-SGA
The score for PG-SGA consists in medical history (weight
loss, symptoms correlated to diet, food intake and func-
tional capacity) compiled by the patient using a chart and a
physical examination carried out by the examiner, who
establishes fat reserves, muscle and fluid status.
Points (0–4) were assigned for each PG-SGA compo-
nent which depend on the impact upon the nutritional
status. Normally points go from a minimum of 0 to a
maximum of 35; the higher the points are, the higher the
risk of malnutrition is. Health personnel who are well-
trained in using the PG-SGA score (physician, biologist-
nutritionist, dietitian, nurse) assigned a score to each
patient.
Answers supplied by patients in the chart of the PG-
SGA were initially assessed by the examiner and subse-
quently assigned an overall score (SGA-B) or severe
malnutrition (SGA-C) [21].
Spitzer index
Quality of life measured with the Spitzer Index is calcu-
lated by assigning points from 0 (the worst) to 10 (the best)
after answering five questions on activities carried out,2 Aminotrofic: Errekappa Euroterapici, Milano.
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daily life, perception of health, social support and habits
[22].
Answers supplied by patients in the PG-SGA section
with boxes to be ticked are initially assessed by the
examiner.
Statistical analysis
Statistical analysis was carried out using the student T-test
which was performed according with the SPSS Program.
The traditional Chi-square and Fisher’s extraction tests
were used to analyse the quantitative differences in the
univaried analysis. Wilcoxon’s non-parametric test was
adopted for the analysis of the Spitzer Index. P values
B0.05 were considered statistically significant.
Results
Patient data for each group are reported in Table 2.
The patients under examination showed a moderate state
of malnutrition at the beginning (SGA grade B). At T0
average weight was 64.41 kg and BMI 23.3 kg/m2 group A
and 60.17 kg and 22.11 kg/m2 in group B.
Physical activity level (PAL) of an individual was cal-
culated as the ratio between total energy expenditure and
resting energy during the course of the day (24 h). In
summary the more an individual is active the higher the
PAL. A low PAL is defined as \1.49, an average PAL is
approximately 1.5 and a high PAL is[1.9. At T0 in group
A, PAL was 1.52 while for group B it was 1.34.
Nutritional support with AFC did not have a significant
effect upon the anthropometric measurements, nor did it
modify nutritional parameters in a significant manner or
phlogosis.
Results were influenced by the extreme seriousness of
patients’ nutritional state and the moderate number of
participants as well as the limited time of treatment.
In fact, as a confirmation of the patients’ already com-
promised clinical conditions, four deaths which were not
related to AFC treatment, were registered during the course
of the trial.
3 in the A group and 1 in the B group.
Descriptive analysis
Considering the nutritional parameters, no significant dif-
ferences concerning dry weight emerged between the
beginning (T0) and the end (T4), both at the infra-group
comparison A/P and the intra-group: comparison between
Dweight T4-T0 A versus Dweight T4-T0 P (weight A to
T0: kg 64.41 ± 6.34; weight A to T4: kg 64.51 ± 7.05:
P = NS; weight P to T0: kg 60.17 ± 11.94; weight P to
T4: kg 59.86 ± 11.43: P = NS); even for BMI values,
significant differences were not observed (BMI dry A to
T0 kg/mq 23.3 ± 3.12; BMI dry A to T4: 23.34 ± 3.37:
P = NS; BMI dry B to T0: 22.11 ± 3.38; BMI dry A to
T4: 22.11 ± 3.36: P = NS).
As regarding the biochemical parameters, significant
differences were observed between pre-albumin value to
T0 in the univariated analysis but not in the multivariate
one (Pre-albumin A to T0: 30.12 ± 7.23; Pre-albumin A to
T4: 28.91 ± 5.8; Pre-albumin P to T0: 22.51 ± 6.04; Pre-
albumin P to T4: 26.10 ± 9.82); non-statistically significant
differences were observed in both statistical analyses for
Albumin (Albumin A to T0: 3,805.56 ± 309.04 mg/L; Albu-
min A to T4: 3,551.11 ± 219.11 mg/L; Albumin P to T0:
3,451.43 ± 841.32 mg/L; Albumin P to T4: 3,525.71 ±
369.90 mg/L) and PCR (PCR A to T0: 1.19 ± 1.67 mg/L;
PCR A to T4: 1.02 ± 1.02 mg/L; PCR P to 0: 1.54 ± 1.44 mg/
L; PCR P to T4: 1.41 ± 0.99 mg/L: P = NS).
Table 1 Aminotrofic and
placebo compositions (essential
amino acid supplement, sachets
from 5.5 g equal to 4 g of
amino acids contain the
following active ingredients)
Aminotrofic Isonitrogenous placebo
Leucine 1,250 mg Calcium caseinate 2,150 mg
Lysine 650 mg Malt dextrin 1,605.5 mg
Isoleucine 625 mg Lemon flavour 101113 without sugar 145 mg
Valine 625 mg Aerosil 200 pharma 80 mg
Threonine 350 mg Acetasulfame k 18 mg






Vitamin B6 0.1 mg
Vitamin B1 0.15 mg
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Significant differences were found between Transferrin
values at T0 A versus T0 P (T0-T0 A vs. P) and to T4 A
versus T4 P (T4-T4 A vs. P) and between Transferrin
values at T0 and T4 A versus P: The best result of the
parameter under consideration was observed in group A
(Transferrin A to T0: 171.77 ± 28.87 mg/dL, Transferrin
A to T4: 181.44 ± 38.83 mg/dL: P \ 0.005; Transferrin P
to T0: 160.29 ± 27.46 mg/dL, Transferrin P to T4:
146.57 ± 24.96 mg/dL: P \ 0.005) (Fig. 1).
Among the serum electrolytes, statistically significant
differences were observed for phosphorous values between
the beginning and the end in both the univariate and mul-
tivariate analyses: The lowest concentration was found in
group A (Phosphorous A to T0 3.7 ± 2.07 mEq/L; Phos-
phorous A to T4: 4.3 ± 1.19 mEq/L; Phosphorous P to T0:
5.24 ± 0.8 mEq/L; Phosphorous P to T4: 6.83 ± 4.26
mEq/L: P \ 0.005) (Fig. 2).
No significant differences were observed for the parame-
ters measured by BIA and body composition both when
compared with the infra-group and the intra-group (P = NS).
The estimate for basal metabolism using the armband
calorimetry did not show any significant differences between
Resting Energy Expenditure (REE) values and Total Energy
Expenditure (TEE) values for both the univariate and multi-
variate analyses (REE A to T0: 1,301.11 ± 175.37 kcal/die;
REE A to T4: 1,256.89 ± 102.48 kcal/die; REE P to T0:
1,197.14 ± 190.39 kcal/die; REE P 1,179.43 ± 160.66 kcal/
die to T4; TEE A to T0: 1,973.78 ± 357.23 kcal/die; TEE A
to T4: 1,818.22 ± 209.53 kcal/die; TEE P to T0: 1,611.14 ±
326.69 kcal/die; TEE P to T4: 1,833.86 ± 745.77 kcal:
P = NS).
The majority of patients were unable to undergo the
handgrip strength evaluation and therefore the data could
not be analysed.
Table 2 Anthropometrical-biochemical data
Time T0 Patients group a
m ± ds
T4 = 120 Patients group a
m ± ds
T0 Patients group p
m ± ds
T4 = 120 Patients group p
m ± ds
Habitual weight* 64.41 ± 6.34 64.51 ± 7.05 60.17 ± 11.94 59.86 ± 11.43
BMI* 23.30 ± 3.12 23.34 ± 3.37 22.11 ± 3.38 22.11 ± 3.36
Glycaemia 120.00± 52.40 123.33 ± 63.40 118.83 ± 63.01 105.00 ± 41.68
Creatinine* 10.37 ± 1.85 9.58 ± 1.75 8.58 ± 2.43 8.21 ± 2.84
Pre-albumin* 30.12 ± 7.23 28.91 ± 5.8 22.51 ± 6.04 26.10 ± 9.82
Albumin* 3,805.56 ± 309.04 3,551.11 ± 219.11 3,451.43 ± 841.32 3,525.71 ± 369.90
Transferrin*** 171.77 ± 28.87 181.44 ± 38.83 160.29 ± 27.46 146.57 ± 24.96
Triglycerides 144.78 ± 68.00 164.67 ± 94.00 137.86 ± 54.00 133.14± 26.00
P*** 3.70 ± 2.07 4.30 ± 1.19 5.24 ± 0.8 6.83 ± 4.26
K* 5.46 ± 0.81 5.18 ± 0.65 5.62 ± 0.56 5.09 ± 0.98
Na* 138.11 ± 2.80 138.44 ± 4.19 137.57 ± 1.40 139.86 ± 4.95
Cl* 102.00 ± 3.28 102.56 ± 4.56 102.86 ± 2.04 104.00 ± 5.83
Ca* 9.03 ± 0.57 9.09 ± 0.46 9.38 ± 0.53 9.13 ± 0.89
PCR* 1.07 ± 1.67 1.02 ± 1.02 1.28 ± 1.44 1.41 ± 0.99
QLQ-Spitzer* 9.11 ± 1.27 9.67 ± 0.50 7.14 ± 2.04 8.00 ± 2.31
TEE (armband)* 1,973.78 ± 357.23 1,818.22 ± 209.53 1,611.14 ± 326.69 1,833.86 ± 745.77
REE (armband)* 1,301.11 ± 175.37 1,256.89 ± 102.48 1,197.14 ± 190.39 1,179.43 ± 160.66
Physical activity level
(PAL)*
1.52 ± 0.18 1.45 ± 0.15 1.34 ± 0.15 1.52 ± 0.44
Triceps skinfold* 9.00 ± 4.50 9.61 ± 4.70 9.00 ± 5.30 9.34 ± 5.30
Arm circumference* 27.44 ± 2.90 27.5 ± 2.90 25.64 ± 2.40 26.30 ± 2.20
FFM 43.89 ± 5.82 44.04 ± 6.56 44.06 ± 7.92 43.73 ± 7.47
BCM 19.40 ± 3.63 19.26 ± 3.41 17.66 ± 4.51 16.96 ± 4.21
BF 20.67 ± 6.72 20.80 ± 7.60 16.19 ± 7.15 16.46 ± 7.84
TBW 35.11 ± 4.67 35.23 ± 5.26 34.83 ± 6.60 34.59 ± 6.27
** P \ 0.001
*** P \ 0.005
**** P \ 0.01
***** P \ 0.05
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Discussion
Patients with Chronic Renal Failure (CRF) whether mal-
nourished or in a healthy nutritional state, show an altered
amino acid pattern characterized by a reduced plasmatic
concentration of essential amino acids. The main cause of
the variations in plasma amino acids is due to protein-
calorie malnutrition associated with chronic inflammation
and concomitant CRF as well as long periods of haemod-
ialysis [23], which can be difficulty counteract by means of
spontaneous nutritional intake [24].
Some studies have shown that the use of ketoacids and/
or essential amino acids associated to protein restriction
improves the sensitivity to insulin and hyperparathyroidism
and is compatible with the maintenance of the nutritional
state. Nevertheless, up until now, a significant effect in
delaying the progression of CRF consequently to taking
essential amino acids has not been demonstrated [25].
Moreover precise indications regarding the best protein
supplement support to take during CRF do not exist.
Integrated enteral or parenteral support is necessary
wherever dietary counselling and the use of oral supple-
ments are not sufficient in satisfying nutritional require-
ments [26].
In this current trial we compared a mixture of modified
essential amino acids with the integration of casein protein
in an iso-nitrogenous composition.
From a nutritional perspective, after 4 months of treat-
ment an increase in protein synthesis was noted in group A
compared to group P which was proved by the significant
increase of transferrin. As far as the fat-free mass is con-
cerned, it has been hypothesized that protein synthesis
could be stimulated by an alternative metabolic route
compared to that of the Insulin-Like-Growth-Factor-1
(IGF-1).
It has been hypothesized that protein synthesis could be
stimulated by an alternative metabolic route compared to
the Insulin-Like-Growth-Factor-1 (IGF-1). The flow of
amino acids through the vena porta is the signal for the
secretion of IGF-1 which in turn is responsible for acti-
vating the growth factor which promotes protein synthesis
and inhibits hypercatabolic states [27]. Apart from the
stimulatory role of protein synthesis, IGF-1 appears to have
a direct inhibitory effect on muscular protein catabolism
under stress, thus reducing it.
Recent experiments lead us to think that amino acids can
influence protein synthesis directly through post-tran-
scriptional control [28].
In this trial, a significant increase of transferrin was
observed in the group (group A) treated with a mixture of
essential amino acids with high content of leucine after
4 months of treatment.
The fact that the same effect has not been seen in the group
treated with casein may be reasonably explained by the
special concentration of the mixture of amino acids compared
to those obtained by casein degradation, which allows for a
more rapid re-establishment of protein synthesis.
As a matter of facts, it is well known that the synthesis
of circulating protein (including transferrin) is reduced
later when compared to the fat-free mass (in particular
muscular-skeletal) during the course of protein malnutri-
tion and its re-establishment precedes it. This is explained
teleologically through an attempt to protect the organism
from protein depletion by maintaining the circulating pool
to the detriment of tissutal one.
The stimulating effect of protein synthesis induced by
the AFC mixture, the subject of this study, may be
explained by the critical role that it plays in controlling
protein synthesis correlated to leucine, the essential and
ketogenic amino acid belonging to the family of branched-
chain amino acids, mainly metabolized in peripheral
muscles rather than in the liver as an energetic substrate.
High intake of leucine reduces catabolism and promotes
protein synthesis [29].
Fig. 1 pre-(T0) and post-(T4) AFC treatment (A) vs. placebo (P): A
significant difference can be seen both at T0 and at T4 between the
two groups (A and P) in particular at T4 in group A (*) an increase
can be seen while in group P a reduction in transferrinemia with
(P \ 0.005)
Fig. 2 Phosphatemia in the blood-before (T0) and after 4 months of
(T4) treatment AFC (A) vs. placebo (P): it can be observed that the
increase in the concentration of serum phosphorus is lower in group A
compared to group P and T4 P \ 0.005
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The stimulatory mechanism of protein synthesis is
attributable to the stimulation of the ancestral pathway
m-TOR-kinases independently by insulin: This pathway
could mainly activated in conditions of insulin-resistance
as can be seen during the course of chronic renal failure.
The mixture of amino acids investigated is particularly rich
in branched-chain amino acids which are transported to the
liver for gluconeogenetic purposes and to the intestine as
an energetic substrate strong stimulators of glutamine and
alanine synthesis [30].
Favourable data for branched-chain amino acids, in the
context of malnutrition and anorexia in chronic renal
patients, are also related to a significant antidepressant
effect by interfering with serotonin activity at a cerebral
level and by inhibiting the hyper-pressure of the proteolytic
muscle metabolic routes [31].
In an early trial carried out on 25 patients suffering from
rheumatic cachexia, the same AFC mixture experimented
in our study was administered for 12 weeks and induced an
increase in the fat-free mass and total proteins, and an
improvement in the patients’ overall physical condition
[32].
Another more recent trial involving 41 patients with
muscle wasting demonstrated that AFC was capable of
increasing the fat-free mass (assessed using DEXA) and
significantly reducing some insulin-resistance markers such
as TNF alpha [33].
These results agree in part with those observed in an
open non-randomised phase II trial by Madeddu et al., in
malnourished advanced stage(IV) cancer patients treated
for 8 weeks with AFC supplementation. Patients showed a
significant increase in muscular strength (measured using
handgrip strength evaluation) and albuminemia as well as a
reduction in oxidative stress assessed using the D-ROMS
Test. Furthermore, in the same trial, a tendency towards an
increase in body weight and leptine, and a slight decrease
in CRP and IL-6 were observed [30] thus indicating a
possible anti-inflammatory role [32].
With regard to the effect on the fat-free mass, in the
present study it has not been observed any decrease of FFM
and BCM, thus confirming a maintenance of body protein
compartment despite the malnutrition.
Thus confirming what has been highlighted in Scog-
namiglio et al. [33]. study who observed that AFC is capable
of improving metabolic control, reducing the level of dila-
tion and left ventricular dysfunction as well as the right
ventricular in type II diabetes patients, improving physical
performance in elderly patients with cardiac failure due to an
improvement in circulation, a better use of oxygen by
muscles and the production of aerobic energy [34].
AFC does not only improve smooth skeletal muscular
performance but also cardiac performance as described by
Macchi et al. [35].
In addition to the favourable role on protein synthesis,
AFC could be particularly indicated during CRF because it
could reduce phosphorus intake which is increased in a
statistically significant manner following casein supple-
mentation.
This increase is explained by the fact that casein is a
protein high in phosphorous and is therefore less appro-
priate compared to others (e.g. Whey protein) which could
be considered as an alternative protein supplement in
underweight CRF patients.
Conclusions
The CRF patient is a chronically malnourished subject with
a high level of protein depletion which strongly influences
a worsening prognosis. This pilot study suggests the AFC
oral supplementation may represent a valid alternative to
intradialytic aminoacid parenteral treatment and may also
allow for a maintenence in blood chemical values and
nutritional status. As a matter of facts this mixture slows
down weight loss and depletion of the fat-free mass
observed during the course of this disease in the advanced
stages, and facilitates recovery thus permitting a reduced
phosphorous load.
Further experience with a greater number of patients for
a longer period of time is necessary in order to obtain an
effective confirmation of AFC’s efficacy.
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